Heart Test Laboratories, Inc.

Equities

HSCS

US42254E3027

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:29:59 06/06/2024 am IST			5-day change	1st Jan Change
5.55 ^USD	+7.77%		-18.29%	-67.54%

24/04	HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	CI
26/03	HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients	CI

Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024

March 15, 2024 at 01:36 am IST

Heart Test Laboratories, Inc. reported earnings results for the third quarter and nine months ended January 31, 2024. For the third quarter, the company reported sales was USD 0.0147 million compared to USD 0.00195 million a year ago. Net loss was USD 1.64 million compared to USD 1.34 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.16 a year ago.
For the nine months, sales was USD 0.0186 million compared to USD 0.00515 million a year ago. Net loss was USD 4.76 million compared to USD 4.72 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.64 a year ago.

Latest news about Heart Test Laboratories, Inc.

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	24/04	CI
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients	26/03	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	15/03	CI
Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board	26/02	CI
Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board	12/02	CI
HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board	01/02	CI
Heart Test Laboratories, Inc. has Changed its Name to HeartSciences Inc	17/01	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15/12	CI
Heart Test Laboratories, Inc. announced that it has received $0.934997 million in funding	07/12	CI
Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding	07/12	CI
Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai	06/12	CI
HeartSciences Completes License Agreements on AI Cardiovascular Algorithms With Icahn School of Medicine at Mount Sinai	20/11	MT
Heart Test Laboratories, Inc. announced that it expects to receive $0.934997 million in funding	16/11	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1.085006 million in funding	15/11	CI
Heart Test Laboratories, Inc. Announces That Its Myovista® Wavecgtm Has Been Selected by Cardiact Ltd (?Cardiact?) to Be Used in Its Heart Screening Program of Members of the Association of Garda Sergeants and Inspectors	13/11	CI
Heart Test Laboratories, Inc. announced that it has received $1 million in funding	20/23/20	CI
Sector Update: Health Care Stocks Lower Late Afternoon	19/23/19	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	18/23/18	MT
Heart Test Laboratories Files for $50 Million Mixed Shelf; Shares Drop	18/23/18	MT
Heart Test Laboratories, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	15/23/15	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding	07/23/07	CI
Heart Test Laboratories Has Distribution Accord With Denmark's FJ Medical	31/23/31	MT
Heart Test's MyoVista wavECG Selected by PanaceaFlo for Heart Screening Evaluation Study in Dublin	24/23/24	MT
Heart Test Laboratories, Inc. Announces It?s MyoVista wavECGTM Selection to Be Used in Irish Heart Screening Evaluation	24/23/24	CI
Heart Test Laboratories Gets Patent Allowance Notice From European Patent Office	17/23/17	MT

Chart Heart Test Laboratories, Inc.

Duration

Period

More charts

Company Profile

Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Companyâs initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.

Sector

Advanced Medical Equipment & Technology

Calendar

17/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company